Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026

Phase 3KSI-101Positive

AI Analysis

Summary

Kodiak Sciences completed enrollment in the first pivotal cohort of the Phase 3 PEAK trial evaluating KSI-101 for macular edema secondary to inflammation, with topline clinical data expected in December 2026.

Clinical Trial Data

Phase

Phase 3

Outcome Details

First pivotal cohort enrollment completed; topline data release remains on track for December 2026

Importance:6/10

Sentiment:

0.60

Phase 3KSI-101PEAK trialenrollment completionmacular edemainflammation

Related Companies

$KOD

Read the original article

Published by yahoo_finance on August 6, 2026 11:00 AM

Read Original